Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Nov;64(11):4520–4524. doi: 10.1128/iai.64.11.4520-4524.1996

Antibacterial activity of antileukoprotease.

P S Hiemstra 1, R J Maassen 1, J Stolk 1, R Heinzel-Wieland 1, G J Steffens 1, J H Dijkman 1
PMCID: PMC174407  PMID: 8890201

Abstract

Antileukoprotease (ALP), or secretory leukocyte proteinase inhibitor, is an endogenous inhibitor of serine proteinases that is present in various external secretions. ALP, one of the major inhibitors of serine proteinases present in the human lung, is a potent reversible inhibitor of elastase and, to a lesser extent, of cathepsin G. In equine neutrophils, an antimicrobial polypeptide that has some of the characteristics of ALP has been identified (M. A. Couto, S. S. L. Harwig, J. S. Cullor, J. P. Hughes, and R. I. Lehrer, Infect. Immun. 60:5042-5047, 1992). This report, together with the cationic nature of ALP, led us to investigate the antimicrobial activity of ALP. ALP was shown to display marked in vitro antibacterial activity against Escherichia coli and Staphylococcus aureus. On a molar basis, the activity of ALP was lower than that of two other cationic antimicrobial polypeptides, lysozyme and defensin. ALP comprises two homologous domains: its proteinase-inhibitory activities are known to be located in the second COOH-terminal domain, and the function of its first NH2-terminal domain is largely unknown. Incubation of intact ALP or its isolated first domain with E. coli or S. aureus resulted in killing of these bacteria, whereas its second domain displayed very little antibacterial activity. Together these data suggest a putative antimicrobial role for the first domain of ALP and indicate that its antimicrobial activity may equip ALP to contribute to host defense against infection.

Full Text

The Full Text of this article is available as a PDF (324.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bieth J. G. In vivo significance of kinetic constants of protein proteinase inhibitors. Biochem Med. 1984 Dec;32(3):387–397. doi: 10.1016/0006-2944(84)90046-2. [DOI] [PubMed] [Google Scholar]
  2. Björck L., Akesson P., Bohus M., Trojnar J., Abrahamson M., Olafsson I., Grubb A. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature. 1989 Jan 26;337(6205):385–386. doi: 10.1038/337385a0. [DOI] [PubMed] [Google Scholar]
  3. Couto M. A., Harwig S. S., Cullor J. S., Hughes J. P., Lehrer R. I. eNAP-2, a novel cysteine-rich bactericidal peptide from equine leukocytes. Infect Immun. 1992 Dec;60(12):5042–5047. doi: 10.1128/iai.60.12.5042-5047.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Couto M. A., Harwig S. S., Lehrer R. I. Selective inhibition of microbial serine proteases by eNAP-2, an antimicrobial peptide from equine neutrophils. Infect Immun. 1993 Jul;61(7):2991–2994. doi: 10.1128/iai.61.7.2991-2994.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Diamond G., Zasloff M., Eck H., Brasseur M., Maloy W. L., Bevins C. L. Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3952–3956. doi: 10.1073/pnas.88.9.3952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Drenth J., Low B. W., Richardson J. S., Wright C. S. The toxin-agglutinin fold. A new group of small protein structures organized around a four-disulfide core. J Biol Chem. 1980 Apr 10;255(7):2652–2655. [PubMed] [Google Scholar]
  7. Eisenberg S. P., Hale K. K., Heimdal P., Thompson R. C. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem. 1990 May 15;265(14):7976–7981. [PubMed] [Google Scholar]
  8. Feinstein G., Janoff A. A rapid method of purification of human granulocyte cationic neutral proteases: purification and further characterization of human granulocyte elastase. Biochim Biophys Acta. 1975 Oct 22;403(2):493–505. doi: 10.1016/0005-2744(75)90077-7. [DOI] [PubMed] [Google Scholar]
  9. Franken C., Meijer C. J., Dijkman J. H. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem. 1989 Apr;37(4):493–498. doi: 10.1177/37.4.2926127. [DOI] [PubMed] [Google Scholar]
  10. Kramps J. A., Franken C., Dijkman J. H. ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in human sputum. Am Rev Respir Dis. 1984 Jun;129(6):959–963. doi: 10.1164/arrd.1984.129.6.959. [DOI] [PubMed] [Google Scholar]
  11. Kramps J. A., Franken C., Dijkman J. H. Quantity of anti-leucoprotease relative to alpha 1-proteinase inhibitor in peripheral airspaces of the human lung. Clin Sci (Lond) 1988 Oct;75(4):351–353. doi: 10.1042/cs0750351. [DOI] [PubMed] [Google Scholar]
  12. Kramps J. A., Franken C., Meijer C. J., Dijkman J. H. Localization of low molecular weight protease inhibitor in serous secretory cells of the respiratory tract. J Histochem Cytochem. 1981 Jun;29(6):712–719. doi: 10.1177/29.6.6788837. [DOI] [PubMed] [Google Scholar]
  13. Kramps J. A., Klasen E. C. Characterization of a low molecular weight anti-elastase isolated from human bronchial secretion. Exp Lung Res. 1985;9(1-2):151–165. doi: 10.3109/01902148509061534. [DOI] [PubMed] [Google Scholar]
  14. Kramps J. A., Rudolphus A., Stolk J., Willems L. N., Dijkman J. H. Role of antileukoprotease in the human lung. Ann N Y Acad Sci. 1991;624:97–108. doi: 10.1111/j.1749-6632.1991.tb17010.x. [DOI] [PubMed] [Google Scholar]
  15. Kramps J. A., van Twisk C., Appelhans H., Meckelein B., Nikiforov T., Dijkman J. H. Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain. Biochim Biophys Acta. 1990 Apr 19;1038(2):178–185. doi: 10.1016/0167-4838(90)90202-q. [DOI] [PubMed] [Google Scholar]
  16. Kramps J. A., van der Valk P., van der Sandt M. M., Lindeman J., Meijer C. J. Elastase as a marker for neutrophilic myeloid cells. J Histochem Cytochem. 1984 Apr;32(4):389–394. doi: 10.1177/32.4.6561228. [DOI] [PubMed] [Google Scholar]
  17. Lehrer R. I., Barton A., Ganz T. Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. J Immunol Methods. 1988 Apr 6;108(1-2):153–158. doi: 10.1016/0022-1759(88)90414-0. [DOI] [PubMed] [Google Scholar]
  18. Lehrer R. I., Ganz T. Antimicrobial polypeptides of human neutrophils. Blood. 1990 Dec 1;76(11):2169–2181. [PubMed] [Google Scholar]
  19. Lehrer R. I., Rosenman M., Harwig S. S., Jackson R., Eisenhauer P. Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods. 1991 Mar 21;137(2):167–173. doi: 10.1016/0022-1759(91)90021-7. [DOI] [PubMed] [Google Scholar]
  20. Martin E., Ganz T., Lehrer R. I. Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol. 1995 Aug;58(2):128–136. doi: 10.1002/jlb.58.2.128. [DOI] [PubMed] [Google Scholar]
  21. McElvaney N. G., Hubbard R. C., Birrer P., Chernick M. S., Caplan D. B., Frank M. M., Crystal R. G. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991 Feb 16;337(8738):392–394. doi: 10.1016/0140-6736(91)91167-s. [DOI] [PubMed] [Google Scholar]
  22. McElvaney N. G., Nakamura H., Birrer P., Hébert C. A., Wong W. L., Alphonso M., Baker J. B., Catalano M. A., Crystal R. G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992 Oct;90(4):1296–1301. doi: 10.1172/JCI115994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McNeely T. B., Dealy M., Dripps D. J., Orenstein J. M., Eisenberg S. P., Wahl S. M. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest. 1995 Jul;96(1):456–464. doi: 10.1172/JCI118056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Meckelein B., Nikiforov T., Clemen A., Appelhans H. The location of inhibitory specificities in human mucus proteinase inhibitor (MPI): separate expression of the COOH-terminal domain yields an active inhibitor of three different proteinases. Protein Eng. 1990 Jan;3(3):215–220. doi: 10.1093/protein/3.3.215. [DOI] [PubMed] [Google Scholar]
  25. Miller K. W., Evans R. J., Eisenberg S. P., Thompson R. C. Secretory leukocyte protease inhibitor binding to mRNA and DNA as a possible cause of toxicity to Escherichia coli. J Bacteriol. 1989 Apr;171(4):2166–2172. doi: 10.1128/jb.171.4.2166-2172.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pellegrini A., Thomas U., von Fellenberg R., Wild P. Bactericidal activities of lysozyme and aprotinin against gram-negative and gram-positive bacteria related to their basic character. J Appl Bacteriol. 1992 Mar;72(3):180–187. doi: 10.1111/j.1365-2672.1992.tb01821.x. [DOI] [PubMed] [Google Scholar]
  27. Rudolphus A., Heinzel-Wieland R., Vincent V. A., Saunders D., Steffens G. J., Dijkman J. H., Kramps J. A. Oxidation-resistant variants of recombinant antileucoprotease are better inhibitors of human-neutrophil-elastase-induced emphysema in hamsters than natural recombinant antileucoprotease. Clin Sci (Lond) 1991 Dec;81(6):777–784. doi: 10.1042/cs0810777. [DOI] [PubMed] [Google Scholar]
  28. Schalkwijk J., de Roo C., de Jongh G. J. Skin-derived antileukoproteinase (SKALP), an elastase inhibitor from human keratinocytes. Purification and biochemical properties. Biochim Biophys Acta. 1991 Feb 22;1096(2):148–154. doi: 10.1016/0925-4439(91)90053-c. [DOI] [PubMed] [Google Scholar]
  29. Schill W. B., Schumacher G. F. Radial diffusion in gel for micro determination of enzymes. I. Muramidase, alpha-amylase, DNase 1, RNase A, acid phosphatase, and alkaline phosphatase. Anal Biochem. 1972 Apr;46(2):502–533. doi: 10.1016/0003-2697(72)90324-7. [DOI] [PubMed] [Google Scholar]
  30. Schägger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987 Nov 1;166(2):368–379. doi: 10.1016/0003-2697(87)90587-2. [DOI] [PubMed] [Google Scholar]
  31. Seemüller U., Arnhold M., Fritz H., Wiedenmann K., Machleidt W., Heinzel R., Appelhans H., Gassen H. G., Lottspeich F. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett. 1986 Apr 7;199(1):43–48. doi: 10.1016/0014-5793(86)81220-0. [DOI] [PubMed] [Google Scholar]
  32. Stockley R. A. Measurement of soluble proteins in lung secretions. Thorax. 1984 Apr;39(4):241–247. doi: 10.1136/thx.39.4.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Stockley R. A. alpha-1-Antitrypsin and the pathogenesis of emphysema. Lung. 1987;165(2):61–77. doi: 10.1007/BF02714424. [DOI] [PubMed] [Google Scholar]
  34. Tosi M. F., Zakem H., Berger M. Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest. 1990 Jul;86(1):300–308. doi: 10.1172/JCI114699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Van-Seuningen I., Davril M. Separation of the two domains of human mucus proteinase inhibitor: inhibitory activity is only located in the carboxy-terminal domain. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1587–1592. doi: 10.1016/0006-291x(91)91755-2. [DOI] [PubMed] [Google Scholar]
  36. Wiedow O., Schröder J. M., Gregory H., Young J. A., Christophers E. Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence. J Biol Chem. 1990 Sep 5;265(25):14791–14795. [PubMed] [Google Scholar]
  37. Ying Q. L., Kemme M., Simon S. R. Functions of the N-terminal domain of secretory leukoprotease inhibitor. Biochemistry. 1994 May 10;33(18):5445–5450. doi: 10.1021/bi00184a013. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES